Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Exclusive News A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthored by Jordan Chussler. Date Posted: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. Even so, some recently public stocks deserve attention from conservative investors with buy-and-hold horizons, as they may justify a place in long-term portfolios. While headlines are dominated by political noise, one of the most important financial stories in the world is going virtually unreported. A new documentary reveals a paradigm-shifting technological breakthrough that could underpin the next era of innovation — and potentially create enormous wealth for early investors.
This isn't AI, crypto, or quantum computing. It's something far more foundational — a core technology already shaping today's advances and expected to define the future. Major investors and tech leaders are quietly pouring billions into it, fully aware that history shows these revolutions reward the prepared and punish the careless.
The documentary also explains the risks: why owning the wrong companies — or buying the right ones at the wrong time — could be devastating. To understand what's really happening, and how investors may be able to position intelligently, you can watch the full film here. Click here to see the full documentary One biotechnology company in the healthcare sector that just went public could be one such case. Last Year's IPO Success Stories Last year provides a strong example of why newly public companies shouldn't be dismissed by lower-risk investors. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have chased its nearly 359% gain before the stock hit 30 days on the Nasdaq, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are all high-risk startups. The medical products and services provider, which debuted in December 2025, was founded in 1966 and already carries a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous bacon packages—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it attractive to income investors. After its IPO, with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized radiation doses, minimizing harm to healthy tissue compared with some conventional treatments. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach nearly $35 billion by 2030, a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the predominant player—an important point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts by the Trump administration notably slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the larger raises for a biotech listing in recent memory. The offering generated $318 million in proceeds, giving the firm a market cap around $3.34 billion. According to the company's prospectus, its executive team includes experienced drug developers and commercialization executives, with management having participated in the development of 14 FDA-approved products. On a technical level, Aktis develops targeted alpha radiopharmaceuticals, a newer class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from drawing significant attention from Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares as part of the offering. This builds on a 2024 collaboration between the companies to develop tumor-targeting radiopharmaceuticals; under that agreement, Aktis received $60 million in cash and an equity investment from Lilly, with potential milestone payments that could exceed $1 billion. The significance of Eli Lilly's backing should not be understated. At about $1.01 trillion, Lilly is among the largest Big Pharma companies by market cap. Its net income jumped nearly 109% year-over-year from 2023 to 2024, and that positive trend may continue when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in Aktis Oncology's success.
| 
